US 7632841
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
granted A61PA61P3/10
Quick answer
US patent 7632841 (2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P3/10